Calamos Advisors
AMPH icon

Calamos Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History

Calamos Advisors’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-19,479
Closed -$1.2M – 953
2023
Q4 		$1.2M Buy
+19,479
New +$1.02M 0.01% 652
2022
Q3 		– Sell
-100,942
Closed -$3.51M – 1282
2022
Q2 		$3.51M Buy
100,942
+6,299
+7% +$225K 0.02% 809
2022
Q1 		$3.4M Buy
+94,643
New +$2.68M 0.01% 805

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Calamos Advisors's AMPH Position: Q1 2024 in Review

Calamos Advisors sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2024, closing a stake of 19,479 shares — an estimated $1.2M sold.

Calamos Advisors first reported a position in AMPH in Q1 2022 and held it in 3 quarters. The position peaked at $3.51M in Q2 2022. 270 funds tracked by Wall St. Rank hold AMPH as of Q1 2024.

  • Calamos Advisors reported no remaining Amphastar Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Calamos Advisors sold 19,479 Amphastar Pharmaceuticals shares in Q1 2024, an estimated $1.2M.
  • Calamos Advisors first reported a position in Amphastar Pharmaceuticals in Q1 2022 and held it in 3 quarters.
  • Calamos Advisors's Amphastar Pharmaceuticals position peaked at $3.51M in Q2 2022.
  • 270 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2024.

Based on Calamos Advisors's 13F filing for Q1 2024, filed 8 May 2024.